Firstly, since limited number of LUSC patients with ICI treatment was available to confirm the prognostic value of DLX2, its significant significance might be ignored, while the better ICI treatment outcome in DLX2-low patients was observed in a large sample-size of patients with other cancers. This evidence concerns the gene DLX2 and cancer.